A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
Phase 1
- Conditions
- Crohn's Disease (CD)MedDRA version: 20.0Level: LLTClassification code: 10013099Term: Disease Crohns Class: 10017947Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2024-510727-19-00
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Participant must have completed Study M13-740 through Week 52., If female, participant must be postmenopausal, surgically sterile or on using a birth control method.
Exclusion Criteria
For any reason participant is considered by the investigator to be an unsuitable candidate, Female participant with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study., Participant is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method